Pregled bibliografske jedinice broj: 403625
Genotype-based prediction of BH4-responsiveness in PKU patients
Genotype-based prediction of BH4-responsiveness in PKU patients // Abstracts for the 11th International Congress of Inborn Errors of Metabolism ; u: Molecular Genetics and Metabolism 98 (2009) (1/2) 1-234 ; Abstr. No. 196
San Diego (CA), Sjedinjene Američke Države, 2009. str. 25-25 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 403625 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Genotype-based prediction of BH4-responsiveness in PKU patients
Autori
Heintz, Caroline ; Karačić, Iva ; Meili, David ; Sarnavka, Vladimir ; Thony ; Petković Ramadža, Danijela ; Fumić, Ksenija ; Mardešić, Duško ; Barić, Ivo ; Blau, Nenad
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts for the 11th International Congress of Inborn Errors of Metabolism ; u: Molecular Genetics and Metabolism 98 (2009) (1/2) 1-234 ; Abstr. No. 196
/ - , 2009, 25-25
Skup
International Congress on Inborn Errors of Metabolism (11 ; 2009)
Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 29.08.2009. - 02.09.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
genotype-phenotype correlation; BH4-responsiveness; PKU
Sažetak
One part of phenylalanine hydroxylase (PAH)-deficient patients may benefit from tetrahydrobiopterin (BH4) therapy instead or in addition to the low-protein diet. Diagnosis of BH4-responsiveness is usually done through the newborn screening for PKU, followed by a BH4 loading test. More than 60 specific mutations in the PAH gene, presenting with a substantial residual activity, were identified in BH4-responsive patients. However, there is no accurate correlation between genotype and BH4-responsiveness. The aim of our study was to provide more information on predictive value of BH4-responsive mutations in Croatian PAH-deficient population. We predicted BH4-responsiveness (> 30% blood phenylalanine reduction within 24 hours) in all individuals with at least one mutation expressing in vitro substantial residual activity (>10%). From a group of 127 patients, 62 were selected (based only on the genotype) as potentially BH4- responsive and 39 were loaded with BH4 (20 mg/kg). The overall frequency of BH4-responsiveness was 36% (14 out of 39 patients with 23 different genotypes), significantly less than expected. The most common BH4- responsive genotypes (p.E390G/p.R408W and p.P281L/p.E390G) were corresponding for >30% residual PAH activity. Analysis of predicted relative PAH activities of recombinantly expressed mutant alleles revealed a significant difference (p<0.002) between BH4-responders and non-responders. This study reveals the importance of a full genotype (instead of just a single responsive mutation) for the prediction of BH4-responsiveness. With exception of the p.E390G mutation, single allele mutations are not reliable for the selection of potential BH4-responsive individuals. It seems that a substantial residual PAH activity resulting from a combination of both alleles is needed to predict BH4-responsiveness in PKU patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081870-1885 - Nasljedne metaboličke i ostale monogenske bolesti djece (Barić, Ivo, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Ksenija Fumić
(autor)
Ivo Barić
(autor)
Danijela Petković-Ramadža
(autor)
Duško Mardešić
(autor)
Vladimir Sarnavka
(autor)
Iva Karačić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE